Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41963
Title: Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2017
Citation: BMC Pulm Med.2017 01;(17)1:8
Abstract: Long-term oxygen therapy (LTOT) is the only component of the management of chronic obstructive pulmonary disease (COPD) that improves survival in patients with severe daytime hypoxemia. LTOT is usually provided by a stationary oxygen concentrator and is recommended to be used for at least 15-18 h a day. Several studies have demonstrated a deterioration in arterial blood gas pressures and oxygen saturation during sleep in patients with COPD, even in those not qualifying for LTOT. The suggestion has been made that the natural progression of COPD to its end stages of chronic pulmonary hypertension, severe hypoxemia, right heart failure, and death is dependent upon the severity of desaturation occurring during sleep. The primary objective of the International Nocturnal Oxygen (INOX) trial is to determine, in patients with COPD not qualifying for LTOT but who present significant nocturnal arterial oxygen desaturation, whether nocturnal oxygen provided for a period of 3 years decreases mortality or delay the prescription of LTOT.
PMID: 28069009
URI: https://hdl.handle.net/20.500.12530/41963
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Getafe > Artículos

Files in This Item:
File Description SizeFormat 
PMC5223547.pdf900.81 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.